Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/med.21776 http://scihub22266oqcxt.onion/10.1002/med.21776 33393116!ä!33393116 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Med+Res+Rev 2021 ; 41 (3): 1775-1797 Nephropedia Template TP {{tp|p=33393116|t=2021. Therapeutic targets and potential agents for the treatment of COVID-19 |pdf=|usr=}}{{33393116}} gab.com Text Therapeutic targets and potential agents for the treatment of COVID-19 JO: Med Res Rev http://www.kidney.de/pget.php?&tw=1&pmid=33393116 #FOAvip The outbreak of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has become a global crisis. As of November 9, COVID-19 has already spread to more than 190 countries with 50,000,000 infections and 1,250,000 deaths. Effective therapeutics and drugs are in high demand. The structure of SARS-CoV-2 is highly conserved with those of SARS-CoV and Middle East respiratory syndrome-CoV. Enzymes, including RdRp, M(pro) /3CL(pro) , and PL(pro) , which play important roles in viral transcription and replication, have been regarded as key targets for therapies against coronaviruses, including SARS-CoV-2. The identification of readily available drugs for repositioning in COVID-19 therapy is a relatively rapid approach for clinical treatment, and a series of approved or candidate drugs have been proven to be efficient against COVID-19 in preclinical or clinical studies. This review summarizes recent progress in the development of drugs against SARS-CoV-2 and the targets involved. Twit Text FOAVip Therapeutic targets and potential agents for the treatment of COVID-19 ????Med Res Rev http://www.kidney.de/pget.php?&tw=1&pmid=33393116 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33393116 #FOAvip English Wikipedia <ref>{{Cite pmid|33393116}}</ref> Therapeutic targets and potential agents for the treatment of COVID-19 #MMPMID33393116 Wu Y; Li Z; Zhao YS; Huang YY; Jiang MY; Luo HB Med Res Rev 2021[May]; 41 (3): 1775-1797 PMID33393116show ga The outbreak of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has become a global crisis. As of November 9, COVID-19 has already spread to more than 190 countries with 50,000,000 infections and 1,250,000 deaths. Effective therapeutics and drugs are in high demand. The structure of SARS-CoV-2 is highly conserved with those of SARS-CoV and Middle East respiratory syndrome-CoV. Enzymes, including RdRp, M(pro) /3CL(pro) , and PL(pro) , which play important roles in viral transcription and replication, have been regarded as key targets for therapies against coronaviruses, including SARS-CoV-2. The identification of readily available drugs for repositioning in COVID-19 therapy is a relatively rapid approach for clinical treatment, and a series of approved or candidate drugs have been proven to be efficient against COVID-19 in preclinical or clinical studies. This review summarizes recent progress in the development of drugs against SARS-CoV-2 and the targets involved. |*COVID-19 Drug Treatment[MESH] |Antiviral Agents/*therapeutic use[MESH] |COVID-19/virology[MESH] |Humans[MESH]Therapeutic targets and potential agents for the treatment of COVID-19(epmc).pdf DeepDyve Pubget Overpricing